ArticleBioactive materials2026
3D bioprinting of flap-tissue with heterogenous cells and flexible perfusable vessels.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in bio-manufacturing, the fabrication of large-scale vascularized tissue with heterogeneous cells remains a daunting challenge. To address this challenge, the reverse engineered structured tissue (REST) three-dimensional (3D) bioprinting method was proposed. This strategy enables the seeding and subsequent assembly of multiple tissue-specific constituent cells onto a robust, flexible, 3D biomimetic vascular scaffold with long-term perfusion capability. The material choices for the vessel network and seeding cells could be decoupled, and separate co-culture of multiple seeding cells in a customized bioreactor could be realized. The cellular layers could be reassembled into an engineered tissue by manually folding the robust vessels. Centimeter-scale vascularized skin-flap-like tissues that comprise epidermal, dermal, and adipose layers were engineered with an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.